ICON PLC at Barclays Global Healthcare Conference Transcript
Good afternoon, everybody. I'm Luke Sergott. I cover Life Science Tools and Diagnostics here at Barclays. It's my pleasure. I have Dr. Steve Cutler from -- CEO of ICON. So with that, I guess we can jump right into it. We'll really talk about some NHP stuff, some SVB.
Questions & Answers
So let's talk about your exposure to the SVB and more importantly, not your particular exposure, but have you done the analysis from your clients? And...
Yes, we've done the analysis to the extent that we can. We don't always have 100% transparency on this, Luke. But from our perspective and from what we've done our exposure is extremely low to companies that are exposed to SVB. And so we think it's in the very low single digits from an exposure point of view. So we don't think there's a longer-term or
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
